tiprankstipranks
Trending News
More News >

SynAct Pharma Secures SEK 30 Million Credit Facility to Bolster Financial Stability

Story Highlights
SynAct Pharma Secures SEK 30 Million Credit Facility to Bolster Financial Stability

Confident Investing Starts Here:

The latest announcement is out from SynAct Pharma AB ( (SE:SYNACT) ).

SynAct Pharma AB has secured a SEK 30 million credit facility from Hunter Capital, which extends its financial runway to mid-2026. This financial move is expected to enhance the company’s stability and strengthen its position for strategic partnerships with major pharmaceutical players, particularly as it continues to develop its Rheumatoid Arthritis program and engage with regulatory bodies like the EMA and FDA.

More about SynAct Pharma AB

SynAct Pharma AB is a clinical-stage biotechnology company that specializes in resolving inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, aiding patients in achieving immune balance and overcoming inflammation.

Average Trading Volume: 215,360

Current Market Cap: SEK755.7M

For a thorough assessment of SYNACT stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App